MZT Holdings, Inc., formerly Matritech, Inc., is a biotechnology company principally engaged in the development, manufacture, marketing, distribution and licensing of cancer diagnostic technologies and products. The products it has developed are based on its nuclear matrix protein (NMP) technology. Its first two products, the NMP221 Test Kit and NMP22 BladderChek Test, sales of which represent approximately 91% of the Company’s total revenue for the year ended December 31, 2006, are designed to detect the presence of a specific protein marker in urine correlated with the presence of bladder cancer. The Company’s sales of the NMP22 BladderChek Test are concentrated in the United States and Germany, where its own sales forces sell the NMP22 BladderChek Test directly to prescribing physicians. It has discovered other proteins associated with cervical, breast, prostate and colon cancer. In December 2007, Inverness Medical Innovations, Inc. acquired Matritech, Inc.